Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 564

The DOI matches its Crossref record.

Sildenafil, a novel effective oral therapy for male erectile dysfunction

Boolell, M., Gepi‐Attee, S., Gingell, J.C., Allen, M.J.·1996·British Journal of Urology

Abstract

Objectives: To determine the efficacy and safety of sildenafil, a novel orally active inhibitor of the type‐V cyclic guanosine monophosphate‐specific phosphodiesterase (the predominant isoenzyme in the human corpus cavernosum) on penile erectile activity in patients with male erectile dysfunction of no established organic cause. Patients and methods: Twelve patients (aged 36–63 years) with male erectile dysfunction of no established organic cause were entered into a double‐blind, randomized, placebo‐controlled, crossover study which was conducted in two phases. In the first phase (four‐way crossover), treatment efficacy was evaluated by measurements of penile rigidity using penile plethysmography during visual sexual stimulation at different doses of sildenafil (10, 25 and 50 mg or placebo). In the second phase (two‐way crossover), efficacy was assessed by a diary record of penile erectile activity after single daily doses of sildenafil (25 mg) or placebo for 7 days. Results: The mean (95% confidence interval, CI) duration of rigidity of >80% at the base of the penis was 1.3 min (0.4–3.1) in patients on placebo, 3.5 min (1.6–7.3; P = 0.009) on 10 mg, 8.0 min (3.7–16.7; P = 0.003) on 25 mg and 11.2 min (5.6–22.3; P < 0.001) on 50 mg of sildenafil. The mean (95% CI) duration of rigidity of >80% at the tip of the penis was 1.2 min (0.4–2.7) on placebo and 7.4 min (2.4–8.5; P =0.001) on 50 mg sildenafil. From the diary record of daily erectile activity, the mean (95% CI) total number of erections was significantly higher in patients receiving sildenafil was 6.1 (3.2–11.4), compared with 1.3 (0.5–2.7) in those on placebo; 10 of 12 patients reported improved erectile activity while receiving sildenafil, compared with two of 12 on placebo ( P = 0.018). Six patients on active treatment and five on placebo reported mild and transient adverse events which included headache, dyspepsia and pelvic musculo‐skeletal pain. Conclusion: These results show that sildenafil is a well tolerated and effective oral therapy for male erectile dysfunction with no established organic cause and may represent a new class of peripherally acting drug for the treatment of this condition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1464-410x.1996.10220.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 564

Metadata

Authors
Boolell, M., Gepi‐Attee, S., Gingell, J. C., & Allen, M. J.
Venue
British Journal of Urology
Publisher
Wiley
Published
1996-08
Volume
78
Issue
2
Pages
257-261
ISSN
0007-1331 (ISSN-L)
OpenAlex
W2115742279
Cited by
564
References
0
FWCI
25.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sildenafil, a novel effective oral therapy for male erectile dysfunction. https://app.cochat.ai/papers/10.1046/j.1464-410x.1996.10220.x
The paper
Boolell, M., Gepi‐Attee, S., Gingell, J. C., & Allen, M. J. (1996). Sildenafil, a novel effective oral therapy for male erectile dysfunction. British Journal of Urology. https://doi.org/10.1046/j.1464-410x.1996.10220.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.